Aptar introduced the first connected device for Respiratory Disease – ADHERO

0
477
ADHERO, first connected device, smart device, BlueTooth reusable enabled device, Bluetooth ADHERO device
Source: Aptar

Aptar Pharma, a world leader in a pharma packaging solution, services, and active packaging solutions, is happy to publish that it has partnered with Lupin Limited to begin India’s first connected device for metered-dose inhalers (MDI) called ADHERO. 

This creative add-on smart device designed to support patients with chronic respiratory diseases. And tracks their MDI usage and facilitates improved adherence to their prescribed therapy.
Inhalers are the selected treatment choice for handling the increasing number of chronic respiratory diseases(COPD) in India. However, it calculated that nearly 45 percent of cases do not adhere to their treatment. And it including the filling and refilling of medicines or controlling the prescribed medication schedule. This variable adherence negatively impacts clinical outcomes and the patient’s quality-of-life. 
This new device, ADHERO, is created to enhance patient adherence to therapy. ADHERO is a BlueTooth reusable enabled device that connects to the top of an MDI. 
Features of Smart Connected Device
With built-in sensors, the device traces the patient’s everyday medication routine and using patterns. Patients can reach this report by attaching through Bluetooth ADHERO device to the “MyAdhero” application on their mobile phones. The mobile application additionally features to give reminders, contextual health alerts based on circumstances like the Air Quality Index (AQI) at the patient’s current location. And also allow sending visual analytics. Patients can also allow their doctor access to their report and medical tracing data through the dashboard portal as well as the mobile application.
Aptar Pharma co-operated with Navia Life Care to form the digital ecosystem for the MyAdhero App. It involves the Patient App, Care Provider App, and the Doctor Portal.
Addressing the launch, Rajeev Sibal, Lupin’s President, stated, “Lupin lays great importance on three perspectives of respiratory medicine, particularly disease information, diagnosis, and adherence. The launch of ADHERO will be excellent guidance to patients using metered dose inhalers as well as for physicians to trace adherence. And compliance with therapy, advancing clinical outcomes, and the quality-of-life of patients.”
Source: iOS

LEAVE A REPLY

Please enter your comment!
Please enter your name here